Higher doses of neutralizing antibody could protect humans against HIV
Although the Antibody Mediated Prevention (AMP) study that launched in 2016 failed to show significant efficacy in a pair of clinical trials, Denis Burton argues in a Perspective that the AMP study's results represent a landmark in AIDS research; they show - for the first time - that a broadly neutralizing antibody (bnAb) can protect humans against exposure to some strains of HIV. According to Burton, the AMP study's data - despite not showing a significant difference between the numbers of infected individuals in the treated groups versus those in the placebo groups - still have tremendous implications for future HIV vaccine design and passive bnAb use strategies. The AMP study evaluated the immunotherapeutic ...











